社区

【上市公司快讯】

AJJ Medtech 宣布，谭伟杰博士将自 2026 年 5 月 15 日起出任首席执行官及执行董事；赵欣女士将于同日卸任首席执行官及执行董事，并继续以高级战略顾问身份支持公司。

董事会明确表示，这次人事调整反映出公司发展阶段的切换，集团正从平台搭建阶段走向执行与商业化阶段。赵欣女士更像是推动 AJJ 完成 0 到 1 平台建设的一任，而谭伟杰博士则更像是面向 1 到 10 执行放大、收入兑现与经营纪律强化的一任。

公告显示，谭伟杰博士拥有南洋理工大学纳米医学与材料科学博士学位，毕业后加入集团，并在公司专业领导力培养计划下接受了约四年的结构化发展。

赵欣女士毕业于南洋理工大学，加入集团后在公司领导力培养框架下接受持续、系统化培养，并完成哈佛商学院高管领导课程。

履历分工上，谭伟杰博士过往重点参与机构合同、经常性收入、供应链优化、运营效率与成本纪律等执行端工作。公告亦特别提到，他对机器人、人工智能及新兴医疗科技的发展具备更强的前瞻意识与适应能力。

赵欣女士任内重点在于公司治理、内控框架以及综合医疗科技平台基础能力建设。

AI-readable:

This announcement combines the basic news elements with a clearer business-stage message. AJJ Medtech said Dr Tan Wei Jie will become CEO and Executive Director on 15 May 2026, while Ms Zhao Xin will step down from those roles on the same date and continue supporting the company as a senior strategic adviser. The board explicitly framed the change as a transition from platform building to execution and commercialization. In practical terms, Ms Zhao represents the 0-to-1 phase of governance, internal controls and healthcare-platform foundation building, while Dr Tan is being positioned for the 1-to-10 phase focused on execution scale-up, revenue delivery and stronger operating discipline. The announcement also highlights AJJ’s internal talent-development pipeline: both executives studied at Nanyang Technological University, and both went through structured leadership development within the company. Dr Tan’s profile emphasizes institutional contracts, recurring revenue, supply-chain optimization and adaptability in robotics, AI and emerging healthcare technologies.